229 related articles for article (PubMed ID: 28240049)
1. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
[TBL] [Abstract][Full Text] [Related]
2. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
3. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
Molina-Vila MA; Bertran-Alamillo J; Gascó A; Mayo-de-las-Casas C; Sánchez-Ronco M; Pujantell-Pastor L; Bonanno L; Favaretto AG; Cardona AF; Vergnenègre A; Majem M; Massuti B; Morán T; Carcereny E; Viteri S; Rosell R
Clin Cancer Res; 2014 Sep; 20(17):4647-59. PubMed ID: 24696321
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
6. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
8. TP53 p.R72P genotype is a marker of poor prognosis in lung cancer.
Neumann MP; González MV; Pitiot AS; Santamaría Í; Martínez C; Tardón A; Astudillo A; Balbín M
Cancer Biomark; 2018; 21(4):747-754. PubMed ID: 29286914
[TBL] [Abstract][Full Text] [Related]
9. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
11. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
12. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
13. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
[TBL] [Abstract][Full Text] [Related]
14. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
15. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
16. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
17. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
Kandioler-Eckersberger D; Kappel S; Mittlböck M; Dekan G; Ludwig C; Janschek E; Pirker R; Wolner E; Eckersberger F
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):744-50. PubMed ID: 10096970
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
20. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
